[Primary health care costs in connection with heart failure surveyed: increased use of ACE inhibitors would be beneficial].
Malmberg
I
I
AstraZeneca Sverige AB, Göteborg.
Persson
U
U
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000191:economics; D015331:Cohort Studies; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D017408:Guidelines as Topic; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care / Q000191:economics*; D011379:Prognosis; D011785:Quality Assurance, Health Care; D013548:Sweden
D000806:Angiotensin-Converting Enzyme Inhibitors